Answers are grounded in this paper and cite their sources.
Metastasis is the main cause leading to cancer-related mortality and represents the culmination of a complex, multistep biological process of successive events. It is not a linear process, and involves dynamic and context-dependent interactions between tumor cells and the host microenvironment. The metastatic cascade comprises multiple interconnected biological events such as local invasion, epithelial–mesenchymal plasticity, intravasation, survival within the circulation, immune evasion, pre-metastatic niche formation, extravasation, dormancy, and eventual colonization of distant organs. Notably, these processes are governed not only by tumor-intrinsic factors such genetic and epigenetic alterations alone but also by tumour microenvironment comprising stromal fibroblasts, endothelial cells, immune cells, extracellular matrix remodeling, metabolic adaptation, and systemic inflammatory signaling. Recent developments in research on mechanisms of metastasis have questioned several long-held concepts, including the indispensable role of complete epithelial–mesenchymal transition (EMT), instead highlighting hybrid epithelial–mesenchymal states, collective migration, tumor cell clusters, and organ-specific ecological adaptation as principal determinants of metastatic competence. This narrative review has amalgamated present-day understanding of the metastatic cascade, encompassing local invasion, intravasation, survival in circulation, extravasation, dormancy, and colonization. Emphasis has been placed on epithelial–mesenchymal plasticity, tumor–microenvironment crosstalk, inflammation, senescence-associated secretory phenotypes, angiogenic regulation, and organ-specific colonization. Emerging evidence challenging the universality of epithelial–mesenchymal transition (EMT) and highlighting metastatic dormancy and niche formation is critically appraised. Understanding these mechanisms is essential for developing therapeutic strategies aimed at preventing and treating metastatic disease apart from and in addition to treating established primary site disease.
No takes yet. Share an insight, caveat, or question.
Priyanka Singh (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: